1. In Vitro Activity of Ceftazidime/Avibactam Alone and in Combination With Fosfomycin and Carbapenems Against KPC-producing Klebsiella Pneumoniae.
- Author
-
Romanelli F, De Robertis A, Carone G, Dalfino L, Stufano M, Del Prete R, and Mosca A
- Subjects
- Carbapenems, Drug Combinations, Humans, Klebsiella pneumoniae, Microbial Sensitivity Tests, beta-Lactamases genetics, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Azabicyclo Compounds pharmacology, Ceftazidime pharmacology, Fosfomycin pharmacology, Klebsiella Infections drug therapy
- Abstract
KPC-producing Klebsiella pneumonia (KPC-Kp) represents a major therapeutic challenge in critically ill patients. Ceftazidime-avibactam (CAZ-AVI) is a new effective drug against KPC-Kp but, due to emerging resistant strains during monotherapy, the association with a second antibiotic has been advocated. Therefore, intravenous fosfomycin may be a possible choice for combination therapy. The aim of this study was to evaluate the in vitro susceptibility of CAZ-AVI alone and in combination with fosfomycin and carbapenems against KPC-Kp clinical isolates by E-test method. The combination of CAZ-AVI with carbapenems showed synergistic activity, whereas with fosfomycin showed addictive activity, suggesting that fosfomycin may be a carbapenem-sparing strategy in antimicrobial stewardship programs.
- Published
- 2020